TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Function at 4 months post injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in spectral edge frequency or bispectral index or transcranial Doppler flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Motor speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: increased likelihood of future use of antidepressants and other medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: increased frequency of visits to ambulatory care services
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rates of respiratory depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time of awakening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TC/HDL-C ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Young's modulus of multifidus muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: SF-36 dimensions (body pain and general health)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: soft tissue recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: implant/prosthesis failures
Endpoint domain: Adverse events/effects
Primary endpoint: Remission of GERD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion and mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Achieving individual blood pressure target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean adjusted reduction in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean adjusted reduction in diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Colony count reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: locoregional control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: colostomy-free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-RPM on leg press
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean frequency of urination per night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of moderate/severe intensity chronic neuralgia
Endpoint domain: Adverse events/effects
Primary endpoint: Therapeutic effect of therapy for gouty arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average monthly Medicare expenditures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 24-h intragastric acidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 24-h plasma gastrin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage time that intragastric pH was > 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage time that intragastric pH was > 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time within intended SpO2 target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time below SpO2 target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Events with SpO2 <88% with >180s duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Peptic ulcer disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Infection rates after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Development of somatic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean body weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total serum cholesterol levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Final examination scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Health Utilities Index (HUI)
Endpoint domain: Life impact
Primary endpoint: Antiviral T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma parathyroid hormone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Seizure remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rates of depression recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: probable depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taking adherence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timing adherence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: geometric mean titres (GMTs) post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: frequency of serorises (≥ 4‐fold rise in OPA titres)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of dental fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: chest compression quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSR rate
Endpoint domain: Adverse events/effects
Primary endpoint: DIEPSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End of treatment response (ETR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Women's perceived level of confidence to discuss family planning with a provider
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modern contraceptive prevalence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of excessive scars
Endpoint domain: Adverse events/effects
Primary endpoint: Loss of tissue orientation
Endpoint domain: Adverse events/effects
Primary endpoint: 6-month death-censored graft survival
Endpoint domain: Mortality/survival
Primary endpoint: PSA level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA doubling time (PSADT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of transient ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean heart rate at onset of ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of ischemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perseverative errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of vital bone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of severe retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Contrast-Induced Nephropathy (CIN) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: survival of ARDS
Endpoint domain: Mortality/survival
Primary endpoint: Percentage change of BMD at lumbar spine after 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change of BMD at femoral neck after 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of non-responders at lumbar spine after 3 years
Endpoint domain: Adverse events/effects
Primary endpoint: binge frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total number of nocturnal hypoglycemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cumulative probability of overnight hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: New or worsening morphometric fractures of the thoracolumbar spine
Endpoint domain: Adverse events/effects
Primary endpoint: Time before returning to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Outflow facility increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent VTE
Endpoint domain: Mortality/survival
Primary endpoint: Blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean heart rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: vector densities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: laser operate proficiency scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal size of residual stone fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cost effectiveness of brimonidine/timolol vs dorzolamide/timolol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intracyclic bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent ischemic events requiring repeat catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: symptoms of any angina
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: need for subsequent bypass surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Periodontal healing (PPD reduction and clinical attachment level gain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in plasma cardiac troponin I concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased thrombus formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Asymptomatic myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Food consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean DOLOPLUS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: additional low-impact back pain days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental per-person costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Delivery within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Duration of analgesia (time to remedication)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean global evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain relief scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak and mean urine flow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: obstructive and irritative symptoms associated with BPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time from referral to being off the wait list
Endpoint domain: Mortality/survival
Primary endpoint: Decision quality based on knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality decision being an informed choice consistent with values
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nutrient-stimulated plasma CCK concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Baseline plasma CCK concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of fentanyl doses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain at 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake proportion of targeted food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of exocrine insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Candida infections
Endpoint domain: Adverse events/effects
Primary endpoint: time to 50% improvement in symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to 50% lesion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to 50% culture eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Four-year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Quality Improvement success
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Postprandial TG responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-h glucose responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-h insulin responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hair growth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to best laryngeal view
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for optimisation manoeuvres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain relieving effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased dorsal ACC activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decreased left anterior insula activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiac and stroke volume indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Satisfaction with consultation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Enablement score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain measured by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain detection threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurological status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Identification of abnormal slides (ASCUS+ and LSIL+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bias in NEAP prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: continence recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychometric scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PDSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ki67 staining ratio at 48 hours after dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late re-occlusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Renal dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Composite outcome of death, cardiogenic shock, or reinfarction
Endpoint domain: Mortality/survival
Primary endpoint: Mean normalized systolic ejection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cervical cytology abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adhesive defects at the enamel interface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adhesive defects at the dentin/cementum interface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical fitness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lesion volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of rotavirus gastroenteritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vaccine efficacy against rotavirus disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outpatient visits for rotavirus disease
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac mortality risk
Endpoint domain: Mortality/survival
Primary endpoint: symptom severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of problem‐free days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Glomerular filtration as assessed by creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary microalbumin/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: N‐acetyl glucosaminidase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in visual and objective lameness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viscosity of synovial fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycosaminoglycan concentration in synovial fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in TCRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK non-adherence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morbidity rate
Endpoint domain: Adverse events/effects
Primary endpoint: cost-efficacy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 24-hour urinary levels of AICA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion rates (SPRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Booster response rates (BRRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of NYHA class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathologic diagnosis and Gleason grading of prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rehospitalization risk
Endpoint domain: Mortality/survival
Primary endpoint: Low frequency oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Very low frequency oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response to PPI therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: triglyceride concentration in TRL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: size of TRL particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of TRL particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: contentment and apathy levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: latency bias in affective go/no-go task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decision-making task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes